Navigation Links
Statement on FDA's Approval of XENAZINE(R) for the Treatment of Chorea Associated With Huntington's Disease
Date:8/15/2008

NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease.

"Chorea is a major cause of disability and death in patients with Huntington's disease. Chorea is not just a mere inconvenience; it can prevent Huntington's disease patients from walking, talking, working, watching television and almost every aspect of one's life. We are ecstatic that, through the approval of Xenazine, patients and families will have the option to take the only drug developed specifically for treating the movements of Huntington's disease," said Nancy Wexler, Ph.D., Higgins Professor of Neuropsychology in the departments of neurology and psychiatry at Columbia University and president of the Hereditary Disease Foundation.

"While we are still hopeful we can some day find a cure, the approval of Xenazine is a breakthrough for the Huntington's disease community," said Dr. Wexler.

The approval of Xenazine marks the first and only FDA-approved treatment for any symptom of Huntington's disease.


'/>"/>
SOURCE Hereditary Disease Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement by the Service Employees International Union (SEIU) Concerning Allegations About SEIU Local 6434, United Long Term Care Workers Union
2. Statement of concern on detention of Drs. Kamiar and Arash Alaei by Iranian authorities
3. Statement by Alan Lambert, Scout Executive, National Capital Area Council, Boy Scouts of America (NCAC) Concerning Closure of Goshen Scout Reservation August 3, 2008
4. Pelosi Statement on Congress Sending Consumer Product Safety Legislation to President
5. PCMA Statement on Baucus-Conrad Comparative Effectiveness Legislation
6. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
7. Pelosi Statement on House Passage of Global AIDS Legislation
8. Cord Blood America CEO Announces Statement Regarding Expansion and Company Valuation
9. Statement Regarding Los Angeles City Attorney Enforcement Action
10. Pelosi Statement on the Death of Dr. Michael DeBakey
11. Newt Gingrich Statement on the Loss of Tony Snow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vodori, ... Flow promotional review platform at the Promotional Review Committee Compliance and Best ... marketers streamline the medical, legal, and regulatory review (MLR) process – which ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
Breaking Medicine Technology: